BioSpace News Archive

XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2023 financial results and highlighted recent operational achievements as XOMA accelerates its differentiated biotech royalty and milestone acquisition strategy.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023.

Organon (NYSE: OGN) today announced its results for the second quarter ended June 30, 2023.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions (“AMP-518”).

Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023.

Olink Holding AB announced that the Baylor College of Medicine Human Genome Sequencing Center has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering.

IO Biotech (Nasdaq: IOBT) announced today an abstract related to the company’s Phase 2 basket trial of IO102-IO103 as an investigational agent in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in solid tumors (IOB-022/KN-D38) has been accepted for poster presentation at the ESMO Congress 2023 being held in Madrid from October 20-24, 2023.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2023.

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023.

Mersana Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2023.